Observational studyEuropean journal of pediatrics2025
Public health impact of nirsevimab and reduction of RSV hospitalisation in all infants: early real-world data from Tuscany (Italy) in the 2024-25 RSV season.
Observational study in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Observational
- Letter to the Editor Regarding "Complementary Strategy of Maternal Immunization and Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Among Italian Infants: A Cost-Effectiveness Assessment".Infectious diseases and therapy · 2026Article
- Review
- Parental Acceptance of Nirsevimab for RSV Prevention in Infants Across Two Consecutive Seasons in Emilia-Romagna, Italy.Vaccines · 2026Article
- Long-acting monoclonal antibodies and the evolving landscape of infant respiratory syncytial virus prevention.Pediatric investigation · 2026Article
- Cost-benefit analysis of nirsevimab for respiratory syncytial virus prevention in infants: a population-based study.European journal of pediatrics · 2026Observational
- Impact of Universal Nirsevimab Immunoprophylaxis on RSV-Related Hospitalizations in Infants: A Two-Season Multicenter Study in Northern Italy.Pathogens (Basel, Switzerland) · 2026Observational
- Adolescent pregnancy as a blind spot in RSV prevention: rethinking maternal and infant immunization policies.European journal of public health · 2026Article
- Early and high Influenza A circulation alongside reduced Respiratory Syncytial Virus prevalence during autumn 2025 in paediatric patients attending emergency department.Italian journal of pediatrics · 2026Article
- Respiratory viral infections in children under five during two consecutive autumn-winter seasons.BMC infectious diseases · 2026Observational
- Real-world impact of nirsevimab on RSV hospitalizations in children under 2 years of age: retrospective monocentric study in a large German tertiary pedatric center.Molecular and cellular pediatrics · 2026Article
- Impact of Nirsevimab on Pediatric RSV-Related Lower Respiratory Tract Infections: A Retrospective Pre-Post Observational Study in Tuscany, Italy.Infectious diseases and therapy · 2026Article
- Article
- Epidemiology and clinical impact of pediatric RSV co-infections after the COVID-19 pandemic: a narrative review.Frontiers in pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Real-world evidence on the public health impact of nirsevimab across a full RSV season in Italy is currently lacking, particularly with respect to hospitalisations and admissions to paediatric intensive care units (PICU), and only limited data are available worldwide. This study aimed to evaluate, in a real-world setting, the public health impact of nirsevimab on RSV-related hospitalisations and PICU admissions in Tuscany. This observational retrospective study included all children under one year of age experiencing their first RSV season, i.e., those born between April and March of the 2021-22, 2022-23, 2023-24, and 2024-25 seasons, who were hospitalised at the Meyer Children's Hospital, a tertiary regional paediatric hospital in Tuscany, for respiratory symptoms with RSV confirmed via real-time PCR testing. Starting November 1st 2024, Nirsevimab was offered to all infants born between 1 April, 2024, and 31 March, 2025. The percentage reduction in RSV-related hospitalisations was calculated by comparing the number of hospitalisations observed in 2024/25 with the mean number recorded across the three preceding RSV seasons. Immunization coverage reached around 90%. During the 2024-2025 RSV season, RSV-related. hospitalisations decreased by 82.1% among infants eligible for immunization, by 83.2% among those born during the RSV season, and by 81.5% among those born before the season. PICU admissions decreased by 85.2%, 84.0%, and 86.8%, respectively, in the same groups. High coverage of nirsevimab immunization substantially reduced RSV-related hospitalisations among infants in Tuscany during the 2024-2025 season. The consistent benefits observed across both in-season and out-of-season birth cohorts support a universal immunization program for all infants, including those born from April onward, in Italy. What is Known: • RSV is the leading cause of infant hospitalisations for lower respiratory tract infections, especially in those ≤12 months. Real-world data on season-wide nirsevimab public health impact in Italy were lacking.. What is New: • Universal nirsevimab immunisation in Tuscany led to an 82.1% reduction in RSV-related hospitalisations and 85.2% in PICU admissions in infants eligible for immunization. Findings support universal over selective immunisation to protect all infants entering their first RSV season.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.